Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073931 | 0.75 | PRMT5 (0.46) | ALPLLRRK2DGAT1GRM5MEN1 | |
| SCHEMBL1775926 | 0.74 | LRRK2 (0.42) | ALPLLRRK2GRM5MEN1KMT2A | |
| SCHEMBL2669109 | 0.71 | GRM5 (0.36) | ALPLLRRK2DGAT1KDM4EATM | |
| SCHEMBL21603218 | 0.69 | KEAP1 (0.39) | KEAP1NFE2L2KDM4EGAAMAPK1 | |
| SCHEMBL1776612 | 0.69 | NOTUM (0.37) | ALPLLRRK2NTRK1GRM5MEN1 | |
| SCHEMBL19138410 | 0.69 | ALPL (0.47) | ALPLLRRK2DGAT1NTRK1KDM4E | |
| SCHEMBL16984949 | 0.67 | DGAT1 (0.44) | DGAT1 | |
| SCHEMBL31597695 | 0.67 | PKM (0.41) | ALPLLRRK2GRM5MEN1KMT2A | |
| SCHEMBL2072783 | 0.66 | LRRK2 (0.45) | ALPLLRRK2KDM4EATMGRM5 | |
| SCHEMBL3294692 | 0.65 | GRM5 (0.34) | KDM4EATMGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | GCK, GCKR, HK1 | ALPL 4060/4885LRRK2 4008/4885DGAT1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.